Latest News for: gaucher
Edit
Spur Therapeutics Announces First Patient Dosed in GALILEO-3 Pivotal Clinical Trial of FLT201 for the Treatment of Gaucher Disease Type 1 (Syncona Ltd)
Public Technologies 07 Jul 2026
"Dosing the first patient in our Phase 3 trial is an important step forward in our efforts to redefine what is possible for individuals living with Gaucher disease," said Michael Parini, Chief Executive Officer.
Edit
Gaucher Disease Market is Projected to Boom by 2036 Owing to the Launch of Novel ...
GetNews 26 Jun 2026
Edit
Constantiam Biosciences and Cincinnati Children’s Collaborate to Accelerate First-in-Class Neuronopathic Gaucher Disease Therapies
Nasdaq Globe Newswire 18 Jun 2026
Edit
Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease (Form 6-K) (Sanofi SA)
Public Technologies 08 Jun 2026
Edit
Dothan Eagle
05 Jun 2026
Vice Adm. Robert Gaucher speaks at Austal USA on June 4, 2026. Gaucher spoke at ...
Vice Adm. Robert Gaucher speaks at Austal USA on June 4, 2026. Gaucher spoke at a celebration of the opening of a manufacturing facility dedicated to work for nuclear submarines ... .
Edit
Spur Therapeutics Presents Clinical Insights on Bone Disease Impact of FLT201 in Adults with Gaucher Disease Type 1 (Syncona Ltd)
Public Technologies 05 May 2026
These data are being presented this week during the International Working Group on Gaucher Disease (IWGGD) 2026 Symposium. Bone disease associated with Gaucher disease is a persistent unmet need for affected individuals.
Edit
Spur Therapeutics Presents Clinical Insights on Bone Disease Impact of FLT201 in Adults with Gaucher ...
Nasdaq Globe Newswire 04 May 2026
Edit
Spur Therapeutics To Present New Clinical Data on FLT201 for Gaucher Disease during the IWGGD ...
Nasdaq Globe Newswire 21 Apr 2026- 1